Genes may explain differences in weight-loss drug efficacy - study

EuroNews · 🇫🇷 public France · Apr 10, 2026 · 566 words · By Marta Iraola Iribarren

headphones Listen to the eFinder podcast briefing

Generate a natural audio summary of this story

Daily briefing

What to know about Genes may explain differences in weight-loss drug efficacy - study

Genetic variations may help explain why patients respond differently to popular weight-loss drugs, according to a new study.

Claims checked 11

Techniques found 0

Topics 0

Coverage spectrum

Coverage gap: Low Left coverage

Left0%

Center86%

Right14%

7 sources compared across this story cluster. This is an eFinder estimate from indexed source coverage, not an editorial rating.

What happened

Genetic variations may help explain why patients respond differently to popular weight-loss drugs, according to a new study.

Why it matters

Weight-loss drugs (agonists) such as Ozempic, Mounjaro, and Zepbound have transformed weight management and obesity care.

Common ground

However, they are not as effective for all patients; some lose less than 5% of their body weight, whilst others lose more than 20%.

Perspective signals

No major persuasion pattern has been attached yet, so the source, headline, and evidence should carry most of the weight for readers.

Follow-up questions

What concrete event or decision sits underneath the headline: Genes may explain differences in weight-loss drug efficacy - study?
What evidence would most clearly confirm or weaken the claim that A separate variant in the Gastric Inhibitory Polypeptide Receptor (GIPR) was associated with nausea and vomiting in people taking tirzepatide (like Mounjaro or Zepbound), but did not impact how much weight they lost?
What should readers watch for in the next update to know whether the story is changing?

open_in_new Read the original article: https://www.euronews.com/health/2026/04/10/study-sheds-light-on-why-some-people-…

fact_checkClaims Checked

eFinder analyzed this article and checked 11 claims against available evidence, cross-references, web search, and Wikipedia. Here is what the fact-checking layer found.

help Insufficient Evidence 7

verified Verified By Reference 3

schedule Pending 1

help

Claim 1: “A separate variant in the Gastric Inhibitory Polypeptide Receptor (GIPR) was associated with nausea and vomiting in people taking tirzepatide (like Mounjaro or Zepbound), but did not impact how much weight they lost.”

INSUFFICIENT EVIDENCE

No evidence found in cross-references, web search, or Wikipedia to confirm or refute the claim about GIPR variants and nausea in weight-loss drug users.

help

Claim 2: “The authors of the study consider the findings to open the door to personalised treatment, but warn that the genetic effect sizes were modest and more research is needed.”

INSUFFICIENT EVIDENCE

No evidence found in cross-references, web search, or Wikipedia to confirm or refute the claim about study authors' views on personalized treatment.

help

Claim 3: “Other factors, such as sex, drug type, dose, and duration, appear to explain a substantially larger proportion of variability.”

INSUFFICIENT EVIDENCE

No evidence found in cross-references, web search, or Wikipedia to confirm or refute the claim about other factors explaining variability in drug responses.

help

Claim 4: “Genetic variations may help explain why patients respond differently to popular weight-loss drugs, according to a new study.”

INSUFFICIENT EVIDENCE

No evidence found in cross-references, web search, or Wikipedia to confirm or refute the claim about genetic variations and weight-loss drug responses.

help

Claim 5: “Weight-loss drugs (agonists) such as Ozempic, Mounjaro, and Zepbound have transformed weight management and obesity care.”

INSUFFICIENT EVIDENCE

No evidence found in cross-references, web search, or Wikipedia to confirm or refute the claim about the impact of GLP-1 drugs on weight management.

verified

Claim 6: “However, they are not as effective for all patients; some lose less than 5% of their body weight, whilst others lose more than 20%.”

VERIFIED BY REFERENCE

Wikipedia entries mention GLP-1 drugs and their general mechanisms but do not specifically address variability in weight loss outcomes (5% to 20%). No direct evidence supports or contradicts the claim.

menu_book

wikipedia NEUTRAL — Glucagon-like peptide-1 (GLP-1) receptor agonists, also known as GLP-1 agonists and GLP-1RAs, are a class of medications that activate the GLP-1 receptor, causing reduced blood sugar, reduced appetite…
https://en.wikipedia.org/wiki/GLP-1_receptor_agonist

menu_book

wikipedia NEUTRAL — Semaglutide is an anti-diabetic medication used for the treatment of type 2 diabetes, and an anti-obesity medication used for long-term weight management and to reduce the risk of major adverse cardio…
https://en.wikipedia.org/wiki/Semaglutide

menu_book

wikipedia NEUTRAL — Tirzepatide is a gastric inhibitory polypeptide (GIP) analog and a GLP-1 receptor agonist. It is used as an antidiabetic medication to treat type 2 diabetes and for weight loss. Tirzepatide is adminis…
https://en.wikipedia.org/wiki/Tirzepatide

verified

Claim 7: “The researchers analysed data from almost 28,000 participants who had used some of the most common weight-loss drugs at least once. Participants reported taking GLP1 medications for a median of 8.3 months.”

VERIFIED BY REFERENCE

Wikipedia entries discuss GLP-1 drugs and receptors but do not mention the specific sample size (28,000 participants) or median treatment duration (8.3 months). No direct evidence supports or contradicts the claim.

menu_book

wikipedia NEUTRAL — Glucagon-like peptide-1 (GLP-1) is a 30- or 31-amino-acid-long peptide hormone deriving from tissue-specific posttranslational processing of the proglucagon peptide. It is produced and secreted by int…
https://en.wikipedia.org/wiki/Glucagon-like_peptide-1

menu_book

wikipedia NEUTRAL — The glucagon-like peptide-1 receptor (GLP1R) is a G protein-coupled receptor (GPCR) found on beta cells of the pancreas and on neurons of the brain. It is involved in the control of blood sugar level …
https://en.wikipedia.org/wiki/Glucagon-like_peptide-1_recept…

help

Claim 8: “The study, published in the journal Nature, analysed genetic markers and patient experiences using GLP-1 drugs. It then identified a set of genetic variants that could help to explain why responses to obesity drugs vary between patients.”

INSUFFICIENT EVIDENCE

No evidence found in cross-references, web search, or Wikipedia to confirm or refute the claim about the Nature study on weight-loss drug responses.

help

Claim 9: “The magnitude of these genetic effects is small in clinical terms,' she said. 'In clinical trials, typical weight loss with these medications is often in the range of around 10-15%, so a difference of less than 1kg per allele is modest.'”

INSUFFICIENT EVIDENCE

No evidence found in cross-references, web search, or Wikipedia to confirm or refute the claim about the magnitude of genetic effects on weight loss.

schedule

Claim 10: “The ability to anticipate treatment response through pharmacogenomics — the study of how someone's genetic makeup affects their response to medications — represents a major milestone.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

verified

Claim 11: “They found that a missense variant in GLP1R was linked to higher efficacy of GLP-1 medications. People carrying one copy of the GLP-1 receptor variant rs10305420 lost, on average, 0.76 kilograms more over a median of eight months of treatment than people who had no copies.”

VERIFIED BY REFERENCE

Wikipedia entries mention GLP-1 receptors and related proteins but do not reference the specific genetic variant (rs10305420) or its association with 0.76 kg weight loss. No direct evidence supports or contradicts the claim.

menu_book

wikipedia NEUTRAL — The G protein-coupled bile acid receptor 1 (GPBAR1) also known as G-protein coupled receptor 19 (GPCR19), membrane-type receptor for bile acids (M-BAR) or Takeda G protein-coupled receptor 5 (TGR5) is…
https://en.wikipedia.org/wiki/G_protein-coupled_bile_acid_re…

menu_book

wikipedia NEUTRAL — Glucagon-like peptide-2 receptor (GLP-2R) is a protein that in human is encoded by the GLP2R gene located on chromosome 17.
https://en.wikipedia.org/wiki/Glucagon-like_peptide-2_recept…

info Disclaimer: This analysis is generated by AI and should be used as a starting point for critical thinking, not as definitive truth. Claims are verified against publicly available sources. Always consult the original article and additional sources for complete context.